REFERENCES
- Cancer Facts and Figures. Society. American Cancer Society, Atlanta 2005
- Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J. Clin. 2005; 55(1)10–30, [INFOTRIEVE], [CSA]
- Status of the medical oncology workforce. The American Society of Clinical Oncology. J. Clin. Oncol. 1996; 14(9)2612–2621, [CSA]
- Johnson L. G., Madeleine M. M., Newcomer L. M., Schwartz S. M., Daling J. R. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973–2000. Cancer 2004; 101(2)281–288, [INFOTRIEVE], [CSA], [CROSSREF]
- Daling J. R., Madeleine M. M., Johnson L. G., et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004; 101(2)270–280, [INFOTRIEVE], [CSA], [CROSSREF]
- Roka S., Rasoul-Rockenschaub S., Roka J., Kirnbauer R., Muhlbacher F., Salat A. Prevalence of anal HPV infection in solid-organ transplant patients prior to immunosuppression. Transpl. Int. 2004; 17(7)366–369, [INFOTRIEVE], [CSA], [CROSSREF]
- Cates W. American Health Association Panel: Estimates of the incidence and prevalence of sexually transmitted diseases in the Unites States. Sex Transm. Dis. 1999; 26: S2–S7, [INFOTRIEVE], [CSA]
- Franco E. L., Harper D. M. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005; 23(17-18)2388–2394, [INFOTRIEVE], [CSA], [CROSSREF]
- Da Costa M. M., Hogeboom C. J., Holly E. A., Palefsky J. M. Increased risk of high-grade anal neoplasia associated with a human papillomavirus type 16 E6 sequence variant. J. Infect. Dis. 2002; 185(9)1229–1237, [INFOTRIEVE], [CSA], [CROSSREF]
- Critchlow C. W., Hawes S. E., Kuypers J. M., et al. Effect of HIV infection on the natural history of anal human papillomavirus infection. Aids 1998; 12(10)1177–1184, [INFOTRIEVE], [CSA], [CROSSREF]
- Sathish N., Abraham P., Peedicayil A., Sridharan G., Chandy G. HPV 16 E6 sequence variations in Indian patients with cervical neoplasia. Cancer Lett. 2005, [CSA]
- Yamada T., Wheeler C. M., Halpern A. L., Stewart A. C., Hildesheim A., Jenison S. A. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J. Virol. 1995; 69(12)7743–7753, [INFOTRIEVE], [CSA]
- Arias-Pulido H., Peyton C. L., Torrez-Martinez N., Anderson D. N., Wheeler C. M. Human papillomavirus type 18 variant lineages in United States populations characterized by sequence analysis of LCR-E6, E2, and L1regions. Virology. 2005; 338(1)22–34, [INFOTRIEVE], [CSA], [CROSSREF]
- Chin-Hong P. V., Vittinghoff E., Cranston R. D., et al. Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J. Natl. Cancer Inst. 2005; 97(12)896–905, [INFOTRIEVE], [CSA]
- Wilkin T. J., Palmer S., Brudney K. F., Chiasson M. A., Wright T. C. Anal intraepithelial neoplasia in heterosexual and homosexual HIV-positive men with access to antiretroviral therapy. J. Infect. Dis. 2004; 190(9)1685–1691, [INFOTRIEVE], [CSA], [CROSSREF]
- Clark M. A., Hartley A., Geh J. I. Cancer of the anal canal. Lancet. Oncol. 2004; 5(3)149–157, [INFOTRIEVE], [CSA], [CROSSREF]
- Centers for Disease Control and Prevention, Atlanta 2003; Vol. 15, HIV/AIDS surveillance report
- U.S. Census Bureau current population reports: poverty in the United States. Washington, D.C. 2002, 2003
- Tarantino D., Bernstein M. A. Endoanal ultrasound in the staging and management of squamous-cell carcinoma of the anal canal: potential implications of a new ultrasound staging system. Dis. Colon. Rectum. 2002; 45(1)16–22, [INFOTRIEVE], [CSA], [CROSSREF]
- Mackay S. G., Pager C. K., Joseph D., Stewart P. J., Solomon M. J. Assessment of the accuracy of transrectal ultrasonography in anorectal neoplasia. Br. J. Surg. 2003; 90(3)346–350, [INFOTRIEVE], [CSA], [CROSSREF]
- Hoffman R., Welton M. L., Klencke B., Weinberg V., Krieg R. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int. J. Radiat. Oncol. Biol. Phys. 1999; 44(1)127–131, [INFOTRIEVE], [CSA], [CROSSREF]
- Allal A. S., Mermillod B., Roth A. D., Marti M. C., Kurtz J. M. The impact of treatment factors on local control in T2-T3 anal carcinomas treated by radiotherapy with or without chemotherapy. Cancer 1997; 79(12)2329–2335, [INFOTRIEVE], [CSA], [CROSSREF]
- Myerson R. J., Kong F., Birnbaum E. H., et al. Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome. Radiother. Oncol. 2001; 61(1)15–22, [INFOTRIEVE], [CSA], [CROSSREF]
- Graf R., Wust P., Hildebrandt B., et al. Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. Oncology. 2003; 65(1)14–22, [INFOTRIEVE], [CSA], [CROSSREF]
- Nilsson P. J., Svensson C., Goldman S., Ljungqvist O., Glimelius B. Epidermoid anal cancer: a review of a population-based series of 308 consecutive patients treated according to prospective protocols. Int. J. Radiat. Oncol. Biol. Phys. 2005; 61(1)92–102, [INFOTRIEVE], [CSA], [CROSSREF]
- Peiffert D., Bey P., Pernot M., et al. Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications. Int. J. Radiat. Oncol. Biol. Phys. 1997; 37(2)313–324, [INFOTRIEVE], [CSA], [CROSSREF]
- Hughes L. L., Rich T. A., Delclos L., Ajani J. A., Martin R. G. Radiotherapy for anal cancer: experience from 1979–1987. Int. J. Radiat. Oncol. Biol. Phys. 1989; 17(6)1153–1160, [INFOTRIEVE], [CSA]
- Ferrigno R., Nakamura R. A., Dos Santos Novaes P. E., et al. Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int. J. Radiat. Oncol. Biol. Phys. 2005; 61(4)1136–1142, [INFOTRIEVE], [CSA], [CROSSREF]
- Deniaud-Alexandre E., Touboul E., Tiret E., et al. Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. Int. J. Radiat. Oncol. Biol. Phys. 2003; 56(5)1259–1273, [INFOTRIEVE], [CSA], [CROSSREF]
- John M., Pajak T., Flam M., et al. Dose Escalation in Chemoradiation for Anal Cancer: Preliminary Results of RTOG 92-08. Cancer J. Sci. Am. 1996; 2(4)205, [INFOTRIEVE], [CSA]
- Nigro N. D., Vaitkevicius V. K., Considine B., Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis. Colon. Rectum. 1974; 17(3)354–356, [INFOTRIEVE], [CSA]
- Leichman L., Nigro N., Vaitkevicius V. K., et al. Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. Am. J. Med. 1985; 78(2)211–215, [INFOTRIEVE], [CSA], [CROSSREF]
- Nigro N. D., Seydel H. G., Considine B., Vaitkevicius V. K., Leichman L., Kinzie J. J. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer 1983; 51(10)1826–1829, [INFOTRIEVE], [CSA], [CROSSREF]
- Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996; 348(9034)1049–1054, [CSA], [CROSSREF]
- Bartelink H., Roelofsen F., Eschwege F., et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J. Clin. Oncol. 1997; 15(5)2040–2049, [INFOTRIEVE], [CSA]
- Flam M., John M., Pajak T. F., et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J. Clin. Oncol. 1996; 14(9)2527–2539, [INFOTRIEVE], [CSA]
- Martenson J. A., Lipsitz S. R., Wagner H., Jr., et al. Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study. Int. J. Radiat. Oncol. Biol. Phys. 1996; 35(4)745–749, [INFOTRIEVE], [CSA], [CROSSREF]
- Gerard J. P., Ayzac L., Hun D., et al. Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients. Radiother. Oncol. 1998; 46(3)249–256, [INFOTRIEVE], [CSA], [CROSSREF]
- Hung A., Crane C., Delclos M., et al. Cisplatin-based combined modality therapy for anal carcinoma. Cancer 2003; 97(5)1195–1202, [INFOTRIEVE], [CSA], [CROSSREF]
- Peiffert D., Giovannini M., Ducreux M., et al. High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study. Ann. Oncol. 2001; 12(3)397–404, [INFOTRIEVE], [CSA], [CROSSREF]
- Meropol N. J., Niedzwiecki D., Shank B. (2005) Combined-modality therapy of poor prognosis anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B (CALGB). 2005 GI Cancers Symposium Program/Proceedings, OrlandoFlorida, 2005
- Rodriguez-Bigas M., Eng C. C.H., Crane Hamilton O. C. Surgery and Chemoradiation for Anal Cancer. Advanced Therapy in Surgical Oncology, C Pollock, Ross, Perrier. BC Decker, Hamiton, Ontario 2005, in press, Winter 2005
- Renehan A. G., Saunders M. P., Schofield P. F., O'Dwyer S. T. Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br. J. Surg. 2005; 92(5)605–614, [INFOTRIEVE], [CSA], [CROSSREF]
- Nilsson P. J., Svensson C., Goldman S., Glimelius B. Salvage abdominoperineal resection in anal epidermoid cancer. Br. J. Surg. 2002; 89(11)1425–1429, [INFOTRIEVE], [CSA], [CROSSREF]
- Bai Y. K., Cao W. L., Gao J. D., Liang J., Shao Y. F. Surgical salvage therapy of anal cancer. World J. Gastroenterol. 2004; 10(3)424–426, [INFOTRIEVE], [CSA]
- Jephcott C. R., Paltiel C., Hay J. Quality of life after non-surgical treatment of anal carcinoma: a case control study of long-term survivors. Clin. Oncol. (R. Coll. Radiol.) 2004; 16(8)530–535, [CSA]
- Myerson R. J., Karnell L. H., Menck H. R. The National Cancer Data Base report on carcinoma of the anus. Cancer 1997; 80(4)805–815, [INFOTRIEVE], [CSA], [CROSSREF]
- Eng C., Abbruzzese J., Minsky B. D. Chemotherapy and radiation of anal canal cancer: the first approach. Surg. Oncol. Clin. N. Am. 2004; 13(2)309–320, viii[INFOTRIEVE], [CSA], [CROSSREF]
- Eng C. Anal Cancer. Manual of Clinical Oncology, H. Kantarjian, C. Koller, R. Wolff. McGraw-Hill, New York 2005, in press
- Blazy A., Hennequin C., Gornet J. M., et al. Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis. Colon. Rectum. 2005; 48(6)1176–1181, [INFOTRIEVE], [CSA], [CROSSREF]
- Gupta A., Cerniglia G., Mick R. The use of HIV protease inhibitors as radiosensitizers. AACR, California 2005; A1226, 2005
- Gervaz P., Hahnloser D., Wolff B. G., et al. Molecular biology of squamous cell carcinoma of the anus: a comparison of HIV-positive and HIV-negative patients. J. Gastrointest. Surg. 2004; 8(8)1024–1030, discussion 31[INFOTRIEVE], [CSA], [CROSSREF]
- Sgadari C., Barillari G., Toschi E., et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat. Med. 2002; 8(3)225–232, [INFOTRIEVE], [CSA], [CROSSREF]
- Newlin H. E., Zlotecki R. A., Morris C. G., Hochwald S. N., Riggs C. E., Mendenhall W M. Squamous cell carcinoma of the anal margin. J. Surg. Oncol. 2004; 86(2)55–62, discussion 3[INFOTRIEVE], [CSA], [CROSSREF]
- Papagikos M., Crane C. H., Skibber J., et al. Chemoradiation for adenocarcinoma of the anus. Int. J. Radiat. Oncol. Biol. Phys. 2003; 55(3)669–678, [INFOTRIEVE], [CSA], [CROSSREF]
- Belkacemi Y., Berger C., Poortmans P., et al. Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network. Int. J. Radiat. Oncol. Biol. Phys. 2003; 56(5)1274–1283, [INFOTRIEVE], [CSA], [CROSSREF]
- Fox P. A., Seet J. E., Stebbing J., et al. The value of anal cytology and human papillomavirus typing in the detection of anal intraepithelial neoplasia: a review of cases from an anoscopy clinic. Sex Transm. Infect. 2005; 81(2)142–146, [INFOTRIEVE], [CSA], [CROSSREF]
- Palefsky J. M., Holly E. A., Hogeboom C. J., Berry J. M., Jay N., Darragh T. M. Anal cytology as a screening tool for anal squamous intraepithelial lesions. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 1997; 14(5)415–422, [INFOTRIEVE], [CSA]
- Cranston R. D., Darragh T. M., Holly E. A., et al. Self-Collected Versus Clinician-Collected Anal Cytology Specimens to Diagnose Anal Intraepithelial Neoplasia in HIV-Positive Men. J. Acquir. Immune. Defic. Syndr. 2004; 36(4)915–920, [INFOTRIEVE], [CSA]
- Jay N., Berry J. M., Hogeboom C. J., Holly E. A., Darragh T. M., Palefsky J. M. Colposcopic appearance of anal squamous intraepithelial lesions: relationship to histopathology. Dis. Colon. Rectum. 1997; 40(8)919–928, [INFOTRIEVE], [CSA], [CROSSREF]
- Geipert N. Vaccinating men for HPV: new strategy for preventing cervical cancer in women?. J. Natl. Cancer Inst. 2005; 97(9)630–631, [INFOTRIEVE], [CSA]
- ACT II A Second UK Phase III Anal Cancer Trial: A Trial of Chemoradiation and Maintenance Therapy for Patients with Anal Cancer. 2005, Accessed July 14, 2005, at http://www.ncrn.org.uk/portfolio/data.asp?ID=691, [CSA]
- Rodel C., Grabenbauer G. G., Papadopoulos T., Hohenberger W., Schmoll H. J., Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J. Clin. Oncol. 2003; 21(16)3098–3104, [INFOTRIEVE], [CSA], [CROSSREF]
- Eng C., Crane C., Rosner G. A phase II study of capecitabine plus oxaliplatin and radiation therapy, XELOX-XRT, in locally advanced squamous cell carcinoma of the anal canal: a preliminary toxicity analysis. ASCO GI Symposium. American Society of Clinical Oncology, HollywoodFlorida 2005; A216, 2005; 2005